Products for Research Use Only

Cangrelor (tetrasodium)

CAT: 0804-HY-19638A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19638A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP) -induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist[1][2].
CAS Number
163706-36-3
Product Name Alternative
AR-C69931MX (tetrasodium)
UNSPSC
12352005
Hazard Statement
H302
Target
P2Y Receptor
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Purity
99.96
Solubility
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : 100 mg/mL (ultrasonic)
Smiles
O[C@H]1[C@@H](O)[C@H](N2C3=NC(SCCC(F)(F)F)=NC(NCCSC)=C3N=C2)O[C@@H]1COP(OP(C(Cl)(P(O[Na])(O[Na])=O)Cl)(O[Na])=O)(O[Na])=O
Molecular Formula
C17H21Cl2F3N5Na4O12P3S2
Molecular Weight
864.29
Precautions
H302
References & Citations
[1]Bhattad VB, , et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7 (17) :408.|[2]Zhan T, Wei T, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol. 2020;120:83-92.|[3]Bekő K, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain. J Thromb Haemost. 2017;15 (6) :1223-1235.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
P2Y12 Receptor

Popular Products